News articles about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat negative recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a news sentiment score of -0.07 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.4452094233042 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
Several research firms recently weighed in on MDGL. Cowen began coverage on Madrigal Pharmaceuticals in a research note on Wednesday, February 28th. They issued an “outperform” rating on the stock. Roth Capital upped their price target on Madrigal Pharmaceuticals from $170.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. HC Wainwright began coverage on Madrigal Pharmaceuticals in a research note on Wednesday, November 29th. They issued a “buy” rating and a $54.00 price target on the stock. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Evercore ISI restated an “outperform” rating and issued a $175.00 price target (up previously from $140.00) on shares of Madrigal Pharmaceuticals in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $154.20.
Shares of Madrigal Pharmaceuticals (MDGL) opened at $133.50 on Wednesday. Madrigal Pharmaceuticals has a 52 week low of $13.09 and a 52 week high of $154.75. The company has a market capitalization of $1,832.55, a price-to-earnings ratio of -52.56 and a beta of 1.32.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).